LBTT Press Release

Lifeline Plans Market Introduction as We Enter National Breast Cancer
Month
Wednesday October 1, 11:15 am ET

RENO, Nev.--(BUSINESS WIRE)--Oct. 1, 2003--Jim Holmes, CEO, Lifeline
Biotechnologies Inc. (OTC: LBTT - News), today announced that the
company's NippleScope(TM) has been under investigation in England for
several months by Dr. Kefah Mokbel, a prominent English surgical
oncologist and breast specialist. Based on his results, the company is
in the process of preparing an application for a CE mark, which will
position Lifeline to commence marketing in Europe later this year or
early next year. 

According to Dr. William Reeves, the company's president and founder,
Intraoperative Ductal Endoscopy (IDE) with the NippleScope(TM) is a
merging technique that allows direct visualization of the breast's
internal ductal system. This new technology produces a sharp, clear
video image of the ducts, where it is believed that up to 95% of all
breast cancers form. The initial application will be in patients who
present with a nipple discharge. This new microendoscope will
eliminate
the need for a "blind" surgical resection to determine the cause of
the
discharge.

There is a growing body of evidence and belief that Intraoperative
Ductal Endoscopy has an important role in guiding conserving surgery
for
breast cancer as well as screening of high-risk women. Potential
applications and feasibility of its use in the rapid intervention and
outpatient setting under local anesthesia are being studied.

According to Jonathan Reeves, vice president of operations, every
effort
is being made to meet a "mid-fall" deadline for obtaining a CE mark
for
the NippleScope(TM) and begin introduction of the NippleScope(TM) at
several important medical meetings in Europe and the United States.
Reeves added, "I think the major introduction of this exciting new
product will take place at Europe's major medical meeting in Hamburg,

Germany, were Dr. Mokbel will be presenting a clinical paper
concerning
his experience in using the scope."

Holmes noted this is encouraging news as we enter National Breast
Cancer
Month, for women with nipple discharge as Mokbel has indications that
without this important procedure a vast majority of these surgeries
are
determined to be needless. He went on to say that following the
NippleScope(TM) introduction in Europe, it is expected that the
product
will be, after FDA clearance, introduced in the United States.

Lifeline's Web site: www.lbti.com